Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.

Journal of neuro-oncology - 1 May 2023

Wollring Michael M, Werner Jan-Michael, Ceccon Garry, Lohmann Philipp, Filss Christian P, Fink Gereon R, Langen Karl-Josef, Galldiks Norbert

Abstract excerpt

PET imaging using radiolabeled amino acids in addition to MRI has become a valuable diagnostic tool in the clinical management of patients with brain tumors. This review provides a comprehensive overview of PET studies in glioma patients with a mutation in the isocitrate dehydrogenase gene (IDH). A considerable fraction of these tumors typically show no contrast enhancement on MRI, especially when classified as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amino Acids
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Glioma Diagnosis and Treatment

Share to Isocitrate Dehydrogenase

Share to Medical Imaging Techniques and Applications

Share to Mutation

Share to Positron-Emission Tomography

Source

Open in PubMed Open full text

Identifiers

PMID: 36577872
DOI: 10.1007/s11060-022-04218-x
PMCID: PMC10227162

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas.PMID 36577872Read ↗

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.Semantic proximity Read ↗

Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification - a retrospective analysis.Semantic proximity Read ↗

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensusSemantic proximity Read ↗

The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors.Semantic proximity Read ↗

Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.Semantic proximity Read ↗

Advanced imaging of IDH-mutant gliomas: Precision in diagnosis and management.Semantic proximity Read ↗

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?Semantic proximity Read ↗

The potential of amino acid PET imaging for prediction and monitoring of vorasidenib response in IDH-mutant gliomas.Semantic proximity Read ↗

Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.Semantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.